News · Equities · MarketWatch · Tue, Oct 13, 2026 4:00 PM
Shkreli Faces Contempt Over Alleged Biopharma Stock Influence
Image from the source feed · MarketWatch
FTC and seven states seek contempt against Martin Shkreli for allegedly influencing biopharma shares.
Martin Shkreli, the former pharmaceutical executive known as “Pharma Bro,” has been named by the Federal Trade Commission and seven state attorneys general as a contempt candidate for allegedly influencing biopharmaceutical shares.
The complaint accuses Shkreli of using his public profile and social media presence to sway investor sentiment toward specific biotech names, a practice that regulators say could distort market prices.
Shkreli has previously faced legal challenges, including a 2015 conviction for securities fraud, but this latest action marks a renewed regulatory focus on his post‑conviction conduct.
Regulatory Response
Based on reporting from MarketWatch. Read the original.
OpenBook analysis
Market impact
This development may heighten scrutiny of individuals who influence biotech equities, potentially affecting trading volume and volatility in the sector. Investors in biopharma stocks may watch for regulatory actions that could alter market dynamics. The case could also signal broader enforcement against market manipulation.
General market context for education only, not investment advice.
This briefing was summarized with automated tools from public reporting by MarketWatch and is general market information, not investment advice. Editorial policy & corrections